Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Verve Therapeutics Inc VERV

Healthcare Biotechnology
Verve Therapeutics, Inc. is a clinical-stage genetic medicines company. The Company is focused on developing a new approach to the care of cardiovascular disease (CVD), transforming treatment from chronic management to single-course gene editing medicines. The Company’s lead programs include VERVE-101, VERVE-102, and VERVE-201, which target genes that have been validated as targets for lowering... see more

Recent & Breaking News (NDAQ:VERV)

Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - VERV

Accesswire September 13, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

PR Newswire September 13, 2024

Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - VERV

Accesswire September 13, 2024

VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Stockholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 13, 2024

Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for Investors - Contact Levi & Korsinsky

PR Newswire September 13, 2024

ROSEN, A TOP RANKED LAW FIRM, Encourages Verve Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action First Filed by the Firm - VERV

Newsfile September 12, 2024

VERV LAWSUIT ALERT: Levi & Korsinsky Notifies Verve Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline

Accesswire September 12, 2024

The Schall Law Firm Urges Shareholder Participation In A Lawsuit Against Verve Therapeutics, Inc. For Securities Fraud

Accesswire September 12, 2024

Class Action Filed Against Verve Therapeutics, Inc. (VERV) Seeking Recovery for Investors - Contact Levi & Korsinsky

Accesswire September 12, 2024

VERV STOCKHOLDER ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Verve Therapeutics, Inc. Investors with Losses Have Opportunity to Lead Class Action Lawsuit!

Accesswire September 12, 2024

Verve Therapeutics, Inc. Class Action: The Gross Law Firm Reminds Verve Therapeutics Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

PR Newswire September 12, 2024

Verve Therapeutics, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire September 11, 2024

ONGOING DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of Verve Therapeutics

Accesswire September 11, 2024

Levi & Korsinsky Notifies Shareholders of Verve Therapeutics, Inc. (VERV) of a Class Action Lawsuit and an Upcoming Deadline

Accesswire September 11, 2024

SHAREHOLDER ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Verve Therapeutics, Inc. - VERV

Accesswire September 11, 2024

Verve Therapeutics, Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before October 28, 2024 to Discuss Your Rights - VERV

Accesswire September 11, 2024

Verve Therapeutics Inc Is Being Sued For Possibly Violating Securities Laws And Investors Are Invited By The Schall Law Firm To Reach Out

Accesswire September 11, 2024

VERV Investors Have Opportunity to Lead Verve Therapeutics, Inc. Securities Fraud Lawsuit Filed by the Schall Law Firm

PR Newswire September 11, 2024

Levi & Korsinsky Reminds Verve Therapeutics, Inc. Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of October 28, 2024 - VERV

Accesswire September 11, 2024

VERV INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Reminds Stockholders of Verve Therapeutics, Inc. to Contact the Firm Today!

Accesswire September 11, 2024